Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.56 +0.87 (+3.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 605,564
Open 23.83
Bid (Size) 24.55 (42)
Ask (Size) 24.56 (6)
Prev. Close 23.69
Today's Range 23.62 - 24.57
52wk Range 11.16 - 31.67
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and... 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+34.0%
+34.0%
1 Month
+11.4%
+11.4%
3 Month
+19.0%
+19.0%
6 Month
+51.4%
+51.4%
1 Year
-10.2%
-10.2%

More News

Read More
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice
Via Stocktwits
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Wondering what's happening in today's after-hours session?
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
Via Chartmill
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
From Pacira BioSciences
Via GlobeNewswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via Business Wire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From SkyMedia, LLC
Via GlobeNewswire
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
Via Talk Markets
Topics Stocks / Equities
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via GlobeNewswire
PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 24.56
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 04/11/25 04:00 PM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.09B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.